The US Food and Drug Administration (FDA) today approved updated labelling for the abuse-deterrent formulation of oxycodone hydrochloride controlled-release tablets (OxyContin, Purdue Pharma LP).
The US Food and Drug Administration (FDA) today approved updated labelling for the abuse-deterrent formulation of oxycodone hydrochloride controlled-release tablets (OxyContin, Purdue Pharma LP).
The US Food and Drug Administration (FDA) today approved the combination of doxylamine and pyridoxine (Diclegis, Duchesnay) to treat pregnant women with nausea and vomiting who have not adequately responded to dietary and lifestyle changes, the agency has announced.
Today the Food and Drug Administration (FDA) approved a new formulation of a once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative pain and inflammation in patients who have undergone cataract surgery. The newly approved 0.7% bromfenac ophthalmic solution (Prolensa, Bausch + Lomb) will likely replace the currently available 0.9% bromfenac ophthalmic solution.
The US Food and Drug Administration (FDA) has approved carbinoxamine maleate extended-release (Karbinal ER, Tris Pharma), the first liquid, sustained-release histamine-H1 receptor blocker indicated for the treatment of seasonal and perennial allergic rhinitis in children aged 2 years and older, the company said.
The drug will be available in a 4 mg/5 mL oral suspension.
The US Food and Drug Administration (FDA) has approved long-acting aripiprazole (Abilify Maintena, Otsuka/Lundbeck) for the maintenance treatment of adults with schizophrenia.
FDA核准Osphena使用在中度至重度的停經後的性交疼痛
The US Food and Drug Administration (FDA) has approved ospemifene (Osphena, Shionogi, Inc) for treating moderate to severe dyspareunia in postmenopausal women, the agencyannounced today.
The indication for the oral targeted agent regorafenib (Stivarga, Bayer) has been expanded by the US Food and Drug Administration (FDA); it is now approved for the treatment of gastrointestinal stromal tumors (GIST). Specifically, it is indicated for use in patients with tumors that cannot be surgically removed and no longer respond to imatinib (Gleevec) and sunitinib (Sutent), the 2 other FDA-approved treatments for this disease.
The US Food and Drug Administration (FDA) has approved budesonide extended release tablets (Uceris, Santarus) for the treatment of active mild to moderate ulcerative colitis in adult patients, the manufacturer announced January 16.
The oral therapy pomalidomide (Pomalyst, Celgene) was approved by the US Food and Drug Administration today for use in the treatment of multiple myeloma.
The FDA has approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women 18 and older.
The US Food and Drug Administration has approved 3 different formulations of the selective dipeptidyl peptidase IV inhibitor alogliptin for the treatment of type 2 diabetes.
The US Food and Drug Administration (FDA) today approved the varicella immune globulin preparation Varizig (Cangene) for reducing the severity of chickenpox infections in high-risk individuals when given within 4 days after exposure.
The US Food and Drug Administration (FDA) approved bedaquiline today as part of the treatment regimen for multidrug-resistant tuberculosis (MDR-TB) when other agents are unavailable.
The US Food and Drug Administration (FDA) has approved apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).
The US Food and Drug Administration (FDA) today announced approval of perampanel tablets (Fycompa, Eisai Inc) for treatment of partial-onset seizures in patients with epilepsy 12 years of age and older.
The US Food and Drug Administration (FDA) yesterday approved ocriplasmin intravitreal injection (Jetrea, ThromboGenics, Inc) for the treatment of symptomatic vitreomacular adhesions (VMAs), the agency announced today.
The US Food and Drug Administration (FDA) today approved adalimumab (Humira, Abbott Laboratories) for its seventh use: treating ulcerative colitis.
Adalimumab is now indicated for moderate to severe ulcerative colitis in adults who have not been helped by corticosteroids and other immunosuppressant medicines, the FDA stated in a press release today.
The US Food and Drug Administration (FDA) has approved the oral therapy regorafenib (Stivarga, Bayer) for the treatment of metastatic colorectal cancer.
美國藥檢局核准新藥Linaclotide膠囊 (145ug) 上市,應用在原發性慢性便秘,以及大腸急躁症 (IBS) 合併便秘症。
The US Food and Drug Administration (FDA) approved the drug linaclotide (Linzess, Ironwood Pharmaceuticals) today for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults.